Alternative Strategies and New Cell Lines for High-level Production of Biopharmaceuticals

Modern Biopharmaceuticals: Design, Development and Optimization

Volumn 3, Issue , 2008, Pages 761-777

  Rose, Thomas ^a   Winkler, Karsten ^b   Brundke, Elisabeth ^a   Jordan, Ingo ^a   Sandig, Volker ^a  

^a PROBIOGEN AG   (Germany)

^b NONE

Author keywords

Glycosylated; Heterohybridoma; Hygromycin; Immunoglobulins; Oncogenes

Indexed keywords

EID: 77956945657     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527620982.ch32     Document Type: Chapter

References (43)

1. Berg DT, Burck PJ, Berg DH, Grinnell BW. 1993. Kringle glycosylation in a modified human tissue plasminogen activator improves functional properties. Blood 81, 1312-1322.
2. Helenius A. 1994. How N-linked oligosaccharides affect glycoprotein folding in the endoplasmic reticulum. Mol Biol Cell 5, 253-265.
3. Fiedler K, Simons K. 1995. The role of N-glycans in the secretory pathway. Cell 81, 309-312.
4. Sareneva T, Pirhonen J, Cantell K, Julkunen I. 1995. N-glycosylation of human interferongamma: glycans at Asn-25 are critical for protease resistance. Biochem J 308, 9-14.
5. Shawler DL, Bartholomew RM, Smith LM, Dillman RO. 1985. Human immune response to multiple injections of murine monoclonal IgG. J Immunol 135, 1530-1535.
6. McCafferty J, Griffiths AD, Winter G, Chiswell DJ. 1990. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348, 552-554.
7. Bruggemann M, Spicer C, Buluwela L, Rosewell I, Barton S, Surani MA, Rabbitts TH. 1991. Human antibody production in transgenic mice: expression from 100 kb of the human IgH locus. Eur J Immunol 21, 1323-1326.
8. Lonberg N, Taylor LD, Harding FA, Trounstine M, Higgins KM, Schramm SR, Kuo CC, Mashayekh R, Wymore K, McCabe JG. 1994. Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature 368, 856-859.
9. Goochee CF, Monica T. 1990. Environmental effects on protein glycosylation. Biotechnology 8, 421-427.
10. Hahn TJ, Goochee CF. 1992. Growth-associated glycosylation of transferrin secreted by HepG2 cells. J Biol Chem 267, 23982-23987.
11. Wright A, Morrison SL. 1997. Effect of glycosylation on antibody function: implications for genetic engineering. Trends Biotechnol 15, 26-32.
12. Borrebaeck CA. 1999. Human monoclonal antibodies: the emperor's new clothes? Nat Biotechnol 17, 621.
13. Galili U, Anaraki F, Thall A, Hill-Black C, Radic M. 1993. One percent of human circulating B lymphocytes are capable of producing the natural anti-Gal antibody. Blood 82, 2485-2493.
14. Hoffmann A, Nimtz M, Getzlaff R, Conradt HS. 1995. "Brain-type" N-glycosylation of asialo-transferrin from human cerebrospinal fluid. FEBS Lett 359, 164-168.
15. Mueller-Storm HP, Sogo JM, Schaffner W. 1989. An enhancer stimulates transcription in trans when attached to the promoter via a protein bridge. Cell 58, 767-777.
16. Kermekchiev M, Pettersson M, Matthias P, Schaffner W. 1991. Every enhancer works with every promoter for all the combinations tested: could new regulatory pathways evolve by enhancer shuffling? Gene Expr 1, 71-81.
17. Chen C, Yang MC, Yang TP. 2001. Evidence that silencing of the HPRT promoter by DNA methylation is mediated by critical CpG sites. J Biol Chem 276, 320-328.
18. Wolffe AP, Pruss D. 1996. Targeting chromatin disruption: transcription regulators that acetylate histones. Cell 84, 817-819.
19. Grunstein M. 1997. Histone acetylation in chromatin structure and transcription. Nature 389, 349-352.
20. Wade PA, Pruss D, Wolffe AP. 1997. Histone acetylation: chromatin in action. Trends Biochem Sci 22, 128-132.
21. Cervoni N, Szyf M. 2001. Demethylase activity is directed by histone acetylation. J Biol Chem 276, 40778-40787.
22. Mutskov VJ, Farrell CM, Wade PA, Wolffe AP, Felsenfeld G. 2002. The barrier function of an insulator couples high histone acetylation lev-els with specific protection of promoter DNA from methylation. Genes Dev 16, 1540-1554.
23. Antoniou M, Harland L, Mustoe T, Williams S, Holdstock J, Yague E, Mulcahy T, Griffiths M, Edwards S, Ioannou PA, Mountain A, Crombie R. 2003. Transgenes encompassing dual-promoter CpG islands from the human TBP and HNRPA2B1 loci are resistant to heterochromatin-mediated silencing. Genomics 82, 269-279.
24. Running Deer J, Allison DS. 2004. High-level expression of proteins in mammalian cells using transcription regulatory sequences from the Chinese hamster EF-1 gene. Biotechnol Prog 20, 880-889.
25. Mizuguchi H, Xu Z, Ishii-Watabe A, Uchida E, Hayakawa T. 2000. IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector. Mol Ther 1, 376-382.
26. Urlaub G, Chasin LA. 1980. Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity. Proc Natl Acad Sci USA 77, 4216-4220.
27. Urlaub G, Mitchell PJ, Kas E, Chasin LA, Funanage VL, Myoda TT, Hamlin J. 1986. Effect of gamma rays at the dihydrofolate reductase locus: deletions and inversions. Somat Cell Mol Genet 12, 555-566.
28. Bebbington CR, Renner G, Thomson S, King D, Abrams D, Yarranton GT. 1992. High-level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selectable marker. Biotechnology 10, 169-175.
29. Kaufman RJ, Sharp PA. 1982. Amplification and expression of sequences cotransfected with a modular dihydrofolate reductase complimentary DNA gene. J Mol Biol 159, 601-621.
30. Harding HP, Calfon M, Urano F, Novoa I, Ron D. 2002. Transcriptional and translational control in the Mammalian unfolded protein response. Annu Rev Cell Dev Biol 18, 575-599.
31. Cudna RE, Dickson AJ. 2003. Endoplasmic reticulum signaling as a determinant of recombinant protein expression. Biotechnol Bioeng 81, 56-65.
32. Schlake T, Bode J. 1994. Use of mutated FLP recognition target (FRT) sites for the exchange of expression cassettes at defined chromosomal loci. Biochemistry 33, 12746-12751.
33. Mielke C, Maass K, Tummler M, Bode J. 1996. Anatomy of highly expressing chromosomal sites targeted by retroviral vectors. Biochemistry 35, 2239-2252.
34. Baer A, Schubeler D, Bode J. 2000. Transcriptional properties of genomic transgene integration sites marked by electroporation or retroviral infection. Biochemistry 39, 7041-7049.
35. Jahn S, Niemann B, Winkler T, Kalden JR, von Baehr R. 1994. Expansion of a B-lymphocyte clone producing IgM auto-antibodies encoded by a somatically mutated VHI gene in the spleen of an autoimmune patient. Rheumatol Int 13, 187-196.
36. Sburlati AR, Umana P, Prati EG, Bailey JE. 1998. Synthesis of bisected glycoforms of recombinant IFN-beta by overexpression of beta-1,4-N-acetylglucosaminyltransferase III in Chinese hamster ovary cells. Biotechnol Prog 14, 189-192.
37. Weitzman JB, Yaniv M. 1999. Rebuilding the road to cancer. Nature 400, 401-402.
38. Graham FL, Smiley J, Russell WC, Nairn R. 1977. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 36, 59-74.
39. Shaw G, Morse S, Ararat M, Graham FL. 2002. Preferential transformation of human neuronal cells by human adenoviruses and the origin of HEK 293 cells. FASEB J 16, 869-871.
40. Fallaux FJ, Kranenburg O, Cramer SJ, Houweling A, Van Ormondt H, Hoeben RC, Van Der Eb AJ. 1996. Characterization of 911, a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. Hum Gene Ther 7, 215-222.
41. Fallaux FJ, Bout A, van der Velde I, van den Wollenberg DJ, Hehir KM, Keegan J, Auger C, Cramer SJ, van Ormondt H, van der Eb AJ, Valerio D, Hoeben RC. 1998. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum Gene Ther 9, 1909-1917.
42. Schiedner G, Hertel S, Kochanek S. 2000. Efficient transformation of primary human amniocytes by E1functions of Ad5, generation of new cell lines for adenoviral vector production. Hum Gene Ther 11, 2105-2116.
43. Kim EJ, Kim NS, Lee GM. 1999. Development of a serum-free medium for dihydrofolate reductase-deficient Chinese hamster ovary cells (DG44) using a statistical design: beneficial effect of weaning of cells. In Vitro Cell Dev Biol Anim 35, 178-182.